At a glance
ClinicalIndex Comparison RecordPhase 2Active· 15 enrolled
Drug / intervention
galeterone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
1911GCCC: Open Label, Phase 2 Trial of Galeterone Combined With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Standard Chemotherapy
In Brief
A Phase 2 clinical trial evaluating galeterone and Gemcitabine for Advanced Pancreatic Cancer. Active but no longer recruiting, targeting 15 participants across 1 site.
Detailed Summary
Assess the effectiveness of galeterone in advanced pancreatic adenocarcinoma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Pancreatic Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
202020212022202320242025202620272028
First PostedSep 2019
Enrollment StartDec 2019
TodayJul 2026
Primary CompletionFeb 2027
Study CompletionDec 2027
First PostedSep 20, 2019
Enrollment StartDec 12, 2019
Primary CompletionFeb 17, 2027
Study CompletionDec 31, 2027
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 6.8 years agoPrimary completion in 8 months
Interventions
galeteronedrug
Therapeutic
Gemcitabinedrug
Therapeutic